Type 1 Diabetes
WHO WE ARE
BDI, a 501(c)(3) nonprofit organization located in San Diego, California, focuses on addressing the social, emotional, and psychological barriers to living a long and healthy life with diabetes. To better understand and overcome these obstacles, BDI is actively engaged in research examining the psychological aspects of diabetes and evaluating innovative behavioral interventions. In addition, BDI directly offers an array of unique, behaviorally-oriented products and services for: people with type 1 diabetes; people with type 2 diabetes; parents of children and teens with diabetes; spouses and partners of people with diabetes; and interested health care professionals. Products and services include print materials; online courses and modules, face-to-face workshops and seminars, professional training programs, and an online library of resources.
We invite you to explore the resources available to you from BDI. We also welcome your suggestions for additional resources that might be added to our web site. Thank you!
UPCOMING EVENTS
BDI hosts the San Diego-wide, monthly case consultation meeting for mental health professionals working in the field of diabetes.
October 5, 2022
Dr. Polonsky (BDI President) is the featured guest on the American Diabetes Association’s monthly “Ask the Experts” program.
October 11, 2022
BDI hosts the once-monthly Case Consultation for Diabetes Care Professionals who are not mental health specialists.
October 25, 2022
Dr. Guzman (BDI Clinical Director) will be a key speaker at the American Diabetes Association’s Overcoming Therapeutic Inertia CME Series webinar, “Destigmatizing Diabetes in Clinical Care: Removing Blame and Judgement.”
October 26, 2022
Polonsky presents (virtually) at the Clinical Grand Rounds lecture at the Joslin Diabetes Center. He will be speaking on “Diabetes Distress and Diabetes Burnout.”
October 31, 2022
LATEST NEWS
Welcome to BDI’s October 2022 update!
Events:
- October 5: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at info@behavioraldiabetes.org if you are in the greater San Diego area and would like further information about this program.
- October 11: Dr. Polonsky (BDI President) is the featured guest on the American Diabetes Association’s monthly “Ask the Experts” program. Join us and ask your questions.
- October 25: BDI hosts the once-monthly Case Consultation for Diabetes Care Professionals (who are not mental health specialists). This one-hour interactive Zoom meeting (1 – 2 pm PST) is an opportunity to discuss tough cases together and brainstorm how to best address the behavioral and emotional aspects of diabetes care in the clinical setting. This is limited to only 10 participants each month, so contact us at info@behavioraldiabetes.org if you would like further information and might want to join us.
- October 26: Dr. Guzman (BDI Clinical Director) will be a key speaker at the American Diabetes Association’s Overcoming Therapeutic Inertia CME Series webinar, “Destigmatizing Diabetes in Clinical Care: Removing Blame and Judgement.”
- October 31: Dr. Polonsky is honored to be presenting (virtually) the Clinical Grand Rounds lecture at the Joslin Diabetes Center. He will be speaking on “Diabetes Distress and Diabetes Burnout.”
e-Learning:
“Caring for Patients in Various Stages of Type 1 Diabetes,” an online Medscape Education Roundtable Program, brings together Dr. Jay Skyler, Dr. Kimber Simmons and our own Dr. Polonsky. In this program, the viewer will learn about screening, staging, managing, and monitoring patients at various stages of T1D.
New peer-reviewed, professional publications
Dr. Polonsky was proud to serve as first author on Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.
In an important new study examining depression rates in people with type 2 diabetes, Dr. John Dibato and his colleagues (including Dr. Polonsky as a co-author) have published Temporal trends in the prevalence and incidence of depression and the interplay of comorbidities in patients with young- and usual-onset type 2 diabetes from the USA and the UK.
